VBI Vaccines (VBIV) announced in their recent 10K report that the Company expects to advance its first product candidate into Phase I FDA clinical trials during the first half of 2016.
The Company collected positive data from toxicology trials for their human CMV vaccine. The trials started in April 2015 and lasted for 6 months. The Company seems confident that the information and data attained from these trials will be sufficient to move to Phase I.
This could be the very ground floor before VBIV moves to Phase I. If the data reported from a Phase I trial is anything like the data recorded from VBIV's initial toxicology trial for their human CMV vaccine, early investors could be in a great position.
Over the last month, the stock price has been pushing for new highs. As of 9:40AM today (Friday 2/26), VBIV has already hit as high as $2.135